Dr. Navnit Shah is currently the President
and Chief Science Officer at Kashiv Pharma, LLC. Dr. Shah, received his B.S. in Chemistry and Pharmaceutical Technology from the Gujarat and Bombay University in India, and M.S. and Ph.D. in Pharmaceutics from St. John’s University. Prior to joining Kashiv, he was a Distinguished Scientist in the Pharmaceutical R&D Department at Hoffmann-La Roche. He has over 38 years of industry experience and has published and presented over 85 papers and 150 abstracts in drug delivery areas. He has received numerous awards for his original research in drug delivery, including the Thomas Alva Edison Patent Award in 2005, the Research Leadership Award from the New Jersey Association of Biomedical Research in 2010, and recently received the New Jersey Inventor of the Year Award from the New Jersey Inventor Hall of Fame for his drug delivery technologies.
Dr. Deepak Thassu has over 25 years of experience in Research and Development with leading pharmaceutical companies. He is specialized in the fields of Nanotechnology and Novel Drug Delivery Systems with emphasis on parenteral and ophthalmic delivery systems for bio/pharmaceuticals. Deepak is an inventor and holds several drug delivery and formulation patents. He has authored and edited several books and book chapters. The latest book, "Ocular Drug Delivery System: Barriers and Applications of Nanoparticulate Systems" was published in 2012. Deepak holds degrees in Pharmacy, PhD in Pharmaceutics, and MBA from Cornell University and is currently working as a consultant and a founder principal of DDP consulting a strategic pharmaceutical consulting organization helping to develop advanced drug delivery technologies and 505 b2s.
Dr. Pei-I Chu obtained her B.S. degree in Pharmacy from National Taiwan University, Taiwan. After graduation from college, she came to the US and obtained her M.S. and Ph.D. degrees in Pharmaceutics from University of Florida. Dr. Pei-I worked at leading pharmaceutical companies for over 20 years, where she has gained valuable experience with the challenges encountered with various forms of dosage forms and has expertise in the development of solids, semi-solids and parenterals. In 2008 Dr. Pei- I joined the FDA as a chemistry reviewer. Dr. Pei-I will discuss the regulatory perspective in the development of new products with specific examples of marketed nanotechnology based products.